TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27217345
Drug: Medium-dose ASCs
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ASCs (10 × 10(6) cells)
Study: 27217345
Drug: High-dose ASCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ASCs (50 × 10(6) cells)
Study: 27217345
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of ASCs
Study: 23008325
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) monotherapy
Study: 20362850
Drug: Low fluidic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluidic parameters (aspiration flow rate 25 cc/min; bottle height 70 cm and 90 cm; vacuum ≤400 mm Hg)
Study: 20362850
Drug: High fluidic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluidic parameters (aspiration flow rate 40 cc/min; bottle height 90 cm and 110 cm; vacuum ≤650 mm Hg)
Study: 18613861
Drug: Modafinil 100
Normalized name: modafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 100 mg, 200 mg, and 400 mg single doses (study 1)
Study: 18613861
Drug: Modafinil 100
Normalized name: modafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 100 mg twice daily for 7 days (study 2)
Study: 15970290
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (3.9 mg/week for 6 months)
Study: 11854872
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia during surgery and intravenous opiate analgesia after surgery
Study: 11703279
Drug: Oral liarozole
Normalized name: letrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liarozole 75 mg twice daily for 12 weeks
Study: 8314680
Drug: H.E.L.P. application
Approvals — FDA: no, EMA: no, PMDA: no
Description: H.E.L.P. application (Group A)
Study: 8314680
Drug: H.E.L.P. application
Approvals — FDA: no, EMA: no, PMDA: no
Description: H.E.L.P. application (Group B)
Study: 3725001
Drug: Amitriptyline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (200 mg)
Study: 3725001
Drug: Trazodone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (400 mg)
Study: 31996411
Drug: Amiloride/hydrochlorothiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride/hydrochlorothiazide (5 mg/50 mg daily)
Study: 27180444
Drug: Olmesartan medoxomil/hydrochlorothiazide
Normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg
Study: 27180444
Drug: Olmetec Plus
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmetec Plus 20/12.5 mg
Study: 25910081
Drug: Home food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home food environment characteristics (e.g., healthy shopping, selecting healthy beverages, healthy food preparation, serving behaviors)
Study: 16647914
Drug: Gynecological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynecological treatment plus somatocognitive therapy
Study: 16647914
Drug: Standard gynecological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard gynecological treatment
Study: 1624241
Drug: Nitrofurantoin 50
Normalized name: nitrofurantoin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 50 mg
Study: 1624241
Drug: Trimethoprim 50
Normalized name: trimethoprim 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 50 mg
Study: 6143965
Drug: Anti-LPS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-LPS treatment (freeze-dried human plasma rich in anti-LPS immunoglobulin G)
Study: 6143965
Drug: Anti-LPS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-LPS treatment
Study: 30898550
Drug: Deferoxamine mesylate
Normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine mesylate (32 mg/kg per day) for 3 consecutive days
Study: 30898550
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) infusions for 3 consecutive days
Study: 26899537
Drug: Short-term statin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term statin treatment
Study: 26899537
Drug: High-dose statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statins
Study: 23214255
Drug: Bromocriptine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine + Compound Xuanju Capsule (CXC)
Study: 11094650
Drug: Continuous hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous hormone replacement therapy (HRT)
Study: 8438612
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of a killed typhoid vaccine
Study: 8438612
Drug: Parenteral vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral vaccination
Study: 3514550
Drug: person‐centered insight
Approvals — FDA: no, EMA: no, PMDA: no
Description: person‐centered insight therapy
Study: 25941016
Drug: AVP-825 (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP-825 (22 mg sumatriptan powder)
Study: 17893569
Drug: Low proportions
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low proportions of CD3+CD4+CD69+ cells before treatment
Study: 17893569
Drug: Low proportions
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low proportions of CD3+CD56+ cells before treatment
Study: 11952312
Drug: Sequential CT-guided
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential CT-guided puncture (group B)
Study: 9607383
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg irbesartan
Study: 1700218
Drug: Low-dose 443C81
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 443C81 (0.46 +/- 0.11 microgram/ml)
Study: 1700218
Drug: High-dose 443C81
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 443C81 (1.0 +/- 0.2 microgram/ml)
Study: 1700218
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of 443C81
Study: 21654265
Drug: Allopurinol 200
Normalized name: allopurinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 200 mg/d
Study: 14574579
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x (5 g Cr monohydrate + 2.5 g maltodextrin)/day)
Study: 14574579
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (4 x 7.5 g maltodextrin/day)
Study: 8159193
Drug: Six-week taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-week taper period
Study: 8159193
Drug: Nine-month taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-month taper period
Study: 8159193
Drug: Spikes in
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spikes in the electroencephalogram at tapering
Study: 31486660
Drug: Control (reflecting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (reflecting on daily activities)
Study: 21306457
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (20 minutes daily from the day before surgery to the third postoperative day)
Study: 19967423
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered once a week (QW)
Study: 19967423
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered every 2 weeks (Q2W)
Study: 18929239
Drug: No anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulation therapy (no-heparin arm)
Study: 18929239
Drug: Standard anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation regimen (control arm: 70 to 100 UI/kg unfractionated heparin)
Study: 11806881
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral loratadine, once daily for three days
Study: 10075338
Drug: Fe group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe group (60 mg Fe and 250 microg folate)
Study: 10075338
Drug: Fe+Zn group
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe+Zn group (60 mg Fe, 250 microg folate, and 15 mg Zn)
Study: 8613581
Drug: Daily toothbrushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily toothbrushing programme with fluoride dentifrice
Study: 8613581
Drug: Daily toothbrushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily toothbrushing programme with fluoride dentifrice plus weekly 0.2% fluoride rinse
Study: 31479947
Drug: Adjuvant imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant imatinib treatment
Study: 10390201
Drug: Aminoglycosides administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides administered twice daily
Study: 10390201
Drug: Aminoglycosides administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides administered once daily
Study: 1672278
Drug: Prophylactic somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic somatostatin infusion before, during, and after the procedure
Study: 27748055
Drug: Fulranumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab (1 mg every 4 weeks)
Study: 27748055
Drug: Fulranumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab (3 mg every 4 weeks)
Study: 27748055
Drug: Fulranumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab (10 mg every 8 weeks)
Study: 27748055
Drug: Fulranumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab (all doses)
Study: 23688527
Drug: PCV13 (follow-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (follow-on dose after 1 year)
Study: 11503007
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg twice daily (1 day before treatment and 3 days of concomitant administration)
Study: 11503007
Drug: Rifampin 300
Normalized name: rifampin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 300 mg twice daily (3 days before treatment and 3 days of concomitant administration)
Study: 8007702
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil - CMF)
Study: 3527011
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of almitrine bismesylate twice daily
Study: 3527011
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of almitrine bismesylate twice daily
Study: 30301127
Drug: Flavanol-rich cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich cocoa (2.5 g/day for 12 weeks)
Study: 30301127
Drug: Cocoa-free capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa-free capsules (placebo)
Study: 28988541
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg plus PQP 640 mg
Study: 28988541
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg plus PQP 960 mg
Study: 28988541
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg plus PQP 1440 mg
Study: 28988541
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg plus PQP (all doses)
Study: 28988541
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg plus PQP (in African population)
Study: 28988541
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg plus PQP (in Vietnam)
Study: 28988541
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg plus PQP
Study: 16531905
Drug: CLA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA (5 g.d(‐1))
Study: 12534358
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg (5000 IU) r‐hCG subcutaneously twice each week for 3 months (n=20)
Study: 12534358
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 3 months (n=20)
Study: 9484091
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser treatment (Group A) with varying power levels (0.8 W, 1.0 W, 1.2 W, 1.5 W)
Study: 9484091
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment at different power levels
Study: 6348378
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of methylprednisolone (MP)
Study: 6348378
Drug: Low-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose regimen of methylprednisolone (MP)
Study: 31575537
Drug: Integrated GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated GP care for persistent physical symptoms; details on dosage and duration not available.
Study: 31575537
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waiting list); details on dosage and duration not available.
Study: 27406589
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose bevacizumab (5 mg/kg) plus lomustine (90 mg/m²)
Study: 27406589
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose bevacizumab (10 mg/kg)
Study: 11852292
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/d for 1 week, then 20 mg/d) in depressed patients (n = 18) and half of the nondepressed subgroup (n = 14)
Study: 11852292
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/d for 1 week, then 20 mg/d)
Study: 9787148
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) with autologous stem cell support (early HDT group, n = 91)
Study: 9787148
Drug: Conventional-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose chemotherapy (CCT) regimen (late HDT group, n = 94)
Study: 9787148
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) with autologous stem cell support (early HDT group)
Study: 9787148
Drug: Conventional-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose chemotherapy (CCT) regimen (late HDT group)
Study: 7674688
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers and beta-blockers for rate control
Study: 7674688
Drug: Low-dose anticoagulation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anticoagulation therapy
Study: 7674688
Drug: Amiodarone in
Normalized name: amiodarone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone in low doses
Study: 581950
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg digoxin orally
Study: 581950
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg digoxin i.v.
Study: 26666738
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of branched-chain amino acids (BCAA) solution (N = 20)
Study: 26666738
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of amino acids (AA) solution (N = 21)
Study: 21324747
Drug: Conventional intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intracytoplasmic sperm injection (ICSI)
Study: 21324747
Drug: Intracytoplasmic morphologically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic morphologically selected sperm injection (IMSI) in severe male factor patients
Study: 21324747
Drug: Conventional intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intracytoplasmic sperm injection (ICSI) in severe male factor patients
Study: 18292452
Drug: Preoperative PVB
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative PVB with 20 mL of ropivacaine 0.5%
Study: 18292452
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine 0.5% infusion (CRI) at a 2 mL/h rate for 24 h
Study: 14637276
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment supplemented with antioxidants for 12 weeks
Study: 7956400
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with etoposide (100 mg/m2), cisplatin (25 mg/m2), ifosfamide (1.5 g/m2), and mesna (1.8 g/m2) for 4 days, 3 cycles every 21 days
Study: 3314173
Drug: Non-retard cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-retard cimetidine preparation
Study: 2179096
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (dosage to reduce resting pulse rate by 25%)
Study: 2179096
Drug: Long-term injection
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term injection sclerotherapy
Study: 1097148
Drug: THC 20
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 20 mg + CBN 40 mg
Study: 1097148
Drug: THC 20
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 20 mg + CBD 40 mg
Study: 1097148
Drug: THC 20
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 20 mg + Placebo
Study: 30767409
Drug: 125 g
Normalized name: ASIAN GINSENG 0.125 g ORAL TABLET [Singiso]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 g of frozen red raspberries (RR-125)
Study: 30767409
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g of frozen red raspberries (RR-250)
Study: 30767409
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of frozen red raspberries (Control)
Study: 25832312
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg every 2 weeks and CZP 400 mg every 4 weeks
Study: 21832988
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg) + Active cognitive bias training
Study: 21832988
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg) + Control cognitive bias training
Study: 19627023
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg plus Lidocaine
Study: 19627023
Drug: Granisetron/lidocaine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron/lidocaine combination
Study: 1676524
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg remoxipride
Study: 10525751
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sulpiride
Study: 28492790
Drug: rhBNP (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBNP (0.005 µg kg‐1 min‐1 for 72 hours)
Study: 22082239
Drug: Brief lifestyle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief lifestyle counseling (quarterly PCP visits + brief monthly sessions with lifestyle coaches)
Study: 22082239
Drug: Enhanced brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced brief lifestyle counseling (same as brief lifestyle counseling + meal replacements or weight-loss medication)
Study: 16501036
Drug: Intranasal E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2/NETA [175 microg/275 microg]
Study: 16501036
Drug: Oral E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2/NETA [1 mg/0.5 mg]
Study: 9095401
Drug: Vigabatrin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (150 mg/kg per day)
Study: 9095401
Drug: Hydrocortisone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (15 mg/kg per day)
Study: 1311650
Drug: Subpressor dose
Normalized name: Suppressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min)
Study: 1311650
Drug: Subpressor dose
Normalized name: Suppressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min) during handgrip exercise
Study: 1311650
Drug: Pressor dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min)
Study: 1311650
Drug: Pressor dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min) during isometric exercise
Study: 4017672
Drug: Theophylline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (4 mg/kg twice daily for three days)
Study: 31186395
Drug: DynaCT+DSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DynaCT+DSA treatment group (27 cases)
Study: 31186395
Drug: DSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSA treatment group (30 cases)
Study: 31186395
Drug: DynaCT+DSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DynaCT+DSA treatment group